Home

Jay T. Backstrom

CIK 1796398 · CHIEF EXECUTIVE OFFICER · last filed 2026-07-10

Jay T. Backstrom is a CHIEF EXECUTIVE OFFICER who has filed 18 SEC Form 4 insider transactions across 4 companies since 2020. The most recent filing, for AGIO, was dated Jul 10, 2026. Across all open-market trades the lifetime net is −$1.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $23.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$23.63M

Companies

4

Total Filings

18

Lifetime Open-Market Net

-$1.85M

Filer Profile

Reported Address
SCHOLAR ROCK HOLDING CORPORATION
301 BINNEY STREET, 3RD FLOOR
CAMBRIDGE, MA 02142
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AGIO Director 1,447 $33.60 $48.6K $0 3 2026-07-10
LAVA Therapeutics NV (LVTX) Delisted Director — $1.74 — $0 2 2025-11-17
SRRK CHIEF EXECUTIVE OFFICER 425,561 $55.41 $23.58M -$1.85M 7 2025-03-12
ACCELERON PHARMA INC (XLRN) Delisted EVP, Research and Development 0 $178.75 $0 $0 5 2021-11-22

Recent Filings

18 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-10 AGIO Mixed +1,447 $0 EDGAR
2026-06-23 AGIO Grant (A) — $0 EDGAR
2025-11-17 LAVA Therapeutics NV (LVTX) Delisted Disp (D) — $0 EDGAR
2025-07-10 AGIO Grant (A) — $0 EDGAR
2025-03-12 SRRK Grant (A) +113,570 $0 EDGAR
2025-02-20 SRRK Sell (S) −18,372 -$676.6K EDGAR
2025-02-18 LAVA Therapeutics NV (LVTX) Delisted Grant (A) — $0 EDGAR
2025-01-21 SRRK Sell (S) −22,308 -$986.0K EDGAR
2024-02-20 SRRK Sell (S) −11,614 -$182.8K EDGAR
2024-02-13 SRRK Grant (A) +214,285 $0 EDGAR
Showing 1–10 of 18
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.